Article

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern

2021-11-12

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in a variety of clinical symptoms ranging from no or mild to severe disease. Currently, there are multiple postulated mechanisms that may push a moderate to severe disease into a critical state. Human serum contains abundant evidence of the immune status following infection. Cytokines, chemokines, and antibodies can be assayed to determine the ex...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3612d5e7-ed01-5c58-b9a4-d95c7dcf1f52
DOI: 10.1101/2021.11.10.468174

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concernDOI 10.1101/2021.11.10.468174Read

Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in JapanSemantic proximity Read

Cross-neutralizing activity against SARS-CoV-2 variants in COVID-19 patients: Comparison of four waves of the pandemic in JapanSemantic proximity Read

Neutralization Of SARS-CoV-2 Variants By A Human Polyclonal Antibody Therapeutic (COVID-HIG, NP-028) With High Neutralizing Titers To SARS-CoV-2Semantic proximity Read

Humoral immune response of patients infected by earlier lineages of SARS-CoV-2 neutralizes wild types of the most prevalent variants in BrazilSemantic proximity Read

Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemicSemantic proximity Read

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodiesSemantic proximity Read

Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021–June 2022Semantic proximity Read

Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic.Semantic proximity Read

COVID-19 Neutralizing Antibodies Predict Disease Severity and SurvivalSemantic proximity Read

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesSemantic proximity Read

COVID-19 neutralizing antibodies predict disease severity and survivalSemantic proximity Read

Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19Semantic proximity Read